Form 4: Gilead Sciences Director Kramer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Kelly A. Kramer reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.
Summary
- On May 7, 2025, Kelly A. Kramer, a director of Gilead Sciences, Inc., acquired 1,516 restricted stock units and 6,809 non-qualified stock options.
- The restricted stock units vest immediately and represent the contingent right to receive one share of Gilead Sciences, Inc.'s common stock each.
- The stock options also vest immediately and provide the right to buy 6,809 shares of Gilead Sciences, Inc.'s common stock at a price of $98.9.
- Following these transactions, Kramer directly owns 19,110 restricted stock units and 6,809 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock options and restricted stock units granted to a director. The immediate vesting is a slightly positive signal.
Positives
- The immediate vesting of both the restricted stock units and stock options suggests confidence in the director's continued service and the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors as they can provide insights into management's views on the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used by companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK) to align management's interests with those of shareholders.
- The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness and retention.
Stakeholder Impact
- The grant of stock options and restricted stock units aligns the director's interests with those of shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date of earliest transaction: Acquisition of restricted stock units and stock options. |
| 05/07/2025 | Grant date and vesting date for both restricted stock units and stock options. |
| 05/08/2025 | Date of signature for the Form 4 filing. |
| 05/07/2035 | Expiration date for the non-qualified stock options. |
Keywords
Gilead Sciences, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, GILD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.